Jane Street’s Minerva Neurosciences NERV Stock Holding History

Jane Street’s Portfolio NERV Stock Details NERV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q3	–	Sell	-18,463	Closed	-$533K	–	7653
2020 Q2	$533K	Buy	+18,463	New	+$1.08M	﹤0.01%	4994

Other funds holding NERV

Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

SEI Investments Oaks, Pennsylvania $108B AUM 26.14% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Jane Street's NERV Position: Q1 2022 in Review

Jane Street sold out of Minerva Neurosciences (NERV) in Q1 2022, closing a stake of 1,365 shares — an estimated $9K sold.

Jane Street first reported a position in NERV in Q2 2019 and held it in 6 quarters. The position peaked at $696K in Q2 2020. 33 funds tracked by Wall St. Rank hold NERV as of Q1 2022.

Jane Street reported no remaining Minerva Neurosciences position as of Q1 2022 after selling out during the quarter.
Jane Street sold 1,365 Minerva Neurosciences shares in Q1 2022, an estimated $9K.
Jane Street first reported a position in Minerva Neurosciences in Q2 2019 and held it in 6 quarters.
Jane Street's Minerva Neurosciences position peaked at $696K in Q2 2020.
33 funds tracked by Wall St. Rank held Minerva Neurosciences as of Q1 2022.

Based on Jane Street's 13F filing for Q1 2022, filed 17 May 2022.